Here a trial that may be of interest to anyone looking for a relatively "easy' trial that may in theory increase response rates/duration etc through synergy. It is in Phase 2, so everyone gets the experimental drug and it is added on to the standard of care medications you would be getting anyways. It is open to both KRAS-wildtype and KRAS-Mutant; >10 sites nationwide
It is a drug called "BAX69"; its mechanism is inhibiting "Macrophage Migratory Inhibition Factor (MIF)" Here are a series of links if you are interested in discussing this kind of trial with your MD.
Trial Link: https://clinicaltrials.gov/ct2/show/NCT ... 810&rank=1
Phase 1 side effect & proof of mechanism: http://meetinglibrary.asco.org/content/152141-156
Preclinical paper: http://www.ncbi.nlm.nih.gov/pmc/article ... l-15-1.pdf